Image source: Getty Images
Droneshield vs Pro Medicus shares: Which ASX growth stock comes out on top?
Weighing up Droneshield Ltd (ASX: DRO) and Pro Medicus Ltd (ASX: PME) as growth shares? Both are well-known names in their own fields, but they couldn't be more different. Whether you're into defence tech or backed by healthcare innovation, choosing between Droneshield and Pro Medicus means thinking about more than just which one's made headlines lately. Let's take a closer look at what sets them apart for ASX growth investors.
The case for Droneshield
Droneshield rides the wave in anti-drone and counter-drone technology. The company's artificial-intelligence-driven hardware and software help protect critical infrastructure, venues, and government operations from drone threats – a niche but increasingly important sector. Its products, such as DroneGun and DroneSentry, are in use by militaries, airports, and commercial operators across Australia, the US, and the UK.
From a fundamentals angle, a few things really stand out:
- Market cap: $1.45 billion — Droneshield is a chunky player in Australian defence tech, but much smaller than Pro Medicus.
- P/E ratio: 433.75, which is extremely high on face value. Note, though, Droneshield's earnings per share is negative (-$0.033), so this P/E may be based on adjusted or forward figures rather than traditional trailing earnings.
- Dividend yield: 0.00%. This is a pure growth story — you're not investing here for income today.
Droneshield's share price has had a wild ride recently and is well down for the year, but its underlying business taps into a field where new geographies and customers could drive future bursts of growth.
The case for Pro Medicus
Pro Medicus is no stranger to growth investors. It's a leading Australian medical imaging software company, providing radiology systems and cloud-based solutions for hospitals and health networks, with a particularly strong foothold among US clients. If healthcare digital transformation continues, Pro Medicus is clearly positioned to benefit.
Looking at the key metrics:
- Market cap: $17.31 billion — more than ten times Droneshield's, putting Pro Medicus up with the ASX big hitters.
- P/E ratio: 65.35, reflecting very high growth expectations, but nowhere near the triple-digit figure we see at Droneshield.
- Dividend yield: 0.42%. While modest, Pro Medicus does pay regular, fully franked dividends, which can be appealing for some growth-minded income seekers.
- Earnings per share: 2.536, well into positive territory and supporting sustainable growth alongside dividends.
Pro Medicus has a proven track record of scaling up from Australia to dominate radiology tech for major hospitals worldwide, and its fundamentals show the company is profitable, pays dividends, and holds a healthy valuation compared to its own sector.
Valuation comparison
Here's how the two stack up on key numbers:
| Metric | Droneshield | Pro Medicus |
|---|---|---|
| Market Cap | $1.45 billion | $17.31 billion |
| P/E Ratio | 433.75 | 65.35 |
| Earnings per Share | -0.033 | 2.536 |
| Dividend Yield | 0.00% | 0.42% |
| Franking | – | 100% |
Note: Droneshield's P/E ratio appears mathematically inconsistent with its negative earnings per share. This suggests the P/E may be forward-looking or based on adjusted earnings rather than trailing net profit.
Pro Medicus trades on a much lower P/E than Droneshield, though both are considered highly valued, especially when compared to classical "value" names. Pro Medicus also provides a small fully franked dividend, absent from Droneshield.
Recent share price momentum
Comparing recent share price performance up to 9 October 2026:
- Droneshield: Closed at $1.57 on 9 Oct 2026. Its year-to-date return is a rough -49.2%, with the past few weeks also showing persistent declines after a small spike in late September.
- Pro Medicus: Closed at $165.73 on 9 Oct 2026. Its year-to-date return is also in the red at -24.7%, but well ahead of Droneshield. The recent movement was positive, gaining 4.5% on the day, and showing several up days in the past fortnight.
Both have struggled year-to-date, but Pro Medicus has been the less volatile and better performing of the two over the period measured.
Which is the better buy?
If I need to pick just one as the stronger ASX growth stock, my lean is towards Pro Medicus. While Droneshield is tackling an exciting and rapidly evolving sector, its negative earnings, lack of dividends, and extreme valuation make it a riskier bet for now. Pro Medicus is far from cheap, but its profitability, fully franked dividends (even if small), positive earnings, and less severe drawdown this year all make it the stand-out for me between these two. There's also proven history in scaling complex software, with stickier revenue and wide adoption in the US. I reckon Pro Medicus offers the higher-quality growth profile on the data at hand — which is what I want in my portfolio, even at a premium price tag.
